1      0

2022 Posters

P04 - ILLUMINATE-C, a Single-arm, Phase 3 Study of Lumasiran in Patients with Primary Hyperoxaluria Type 1 and CKD3b-5, Including Those on Hemodialysis

May 23, 2022 7:00pm ‐ May 23, 2022 7:00pm


Understand and recall that lumasiran, an RNAi therapeutic indicated for the treatment of
primary hyperoxaluria type 1 (PH1) to lower urinary oxalate levels in children and adults, can substantially reduce plasma oxalate in patients with PH1 and CKD 3b–5, with an acceptable safety profile through 6-months of treatment.


You must be logged in and own this session in order to post comments.